Example ContractsClausesEscalation
Remove:

I acknowledge that I have reviewed the Corporation’s Code of Conduct. I further acknowledge that I understand and will comply with the terms and standards contained in that Code of Conduct, including but not limited to the prohibition against retaliation, and specifically acknowledge that I have an obligation to report suspected violations of the Code of Conduct pursuant to the Corporation’s Escalation Policy.

/

the selection of the Product for Commercialization in accordance with [Section 2.6] will be made only ​, and, for clarity, if there is ​ of the JSC on the foregoing matter, then a Party may exercise its Opt-Out Right with respect to such Development Candidate and associated Product in accordance with [Section 3.2] (and for clarity without escalation to the Executive Officers or arbitration under [Article 17]);

“Phase Ib Clinical Trial” shall mean the cohort expansion phase of a Phase I Clinical Trial of a Licensed Product after the Dose Escalation Study portion of such Phase I Clinical Trial that includes the dosing of one or more cohorts of patients, the principal purpose of which cohort expansion phase is to evaluate safety, tolerability and indication of efficacy of such Licensed Product in patients.

Pursuant to the Amendment, each Individual Trustee receives at least in annual compensation for services as Trustee. Each year, annual Trustee compensation is adjusted up or down (but not below ) in accordance with changes from the level of 295.5 (the “1981 Escalation Level”) in the All Commodities Producer Price Index (with 1967 = 100 as a base). The All Commodities Producer Price Index is published by the U.S. Department of Labor. The adjustment is made at the end of each fiscal year and is calculated on the basis of the proportion between (a) the level of such index for the November preceding the end of such fiscal year, and (b) the 1981 Escalation Level. Each of the Individual Trustees received in cash compensation for services to the Trust during the fiscal year ended , except Ms. Radke, who received since she joined as a Trustee of the Trust in .

from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company’s principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.

/

Non-payment Disputes. If Expedia and Decolar are unable to resolve any dispute (other than disputes relating to # Expedia Partners, which are addressed in [Sections D.2 and D.3]3] or # payment obligations, which are addressed in [Section E.7.b].ii below) arising under this Agreement within five # Business Days after delivery of a notification of dispute, the Party believing itself to be aggrieved shall request progressive management involvement in the dispute resolution process by written notice to the other Party. The Parties shall use commercially reasonable efforts to arrange personal meetings and/ or telephone conferences as needed. The negotiators shall have the Negotiation Period, including every level of the Escalation Process, in which to attempt to resolve the dispute. If such matter remains unresolved, either Party may exercise any rights available to it with respect to the disputed item under this Agreement or otherwise, including to settle the dispute in accordance with the terms set forth in [Section E.7.l].

the execution, announcement or pendency of this Agreement or the terms hereof (including the identity of the Purchaser) or the announcement, pendency or consummation of the transactions contemplated by this Agreement; # the general conditions or trends in the industries in which the Business operates or in the economy generally or other general business, financial or market conditions; # domestic, foreign or global political conditions, economic, regulatory, financial or capital markets conditions (including interest rates, exchange rates, tariffs, trade wars and credit markets); # any act of civil unrest, civil disobedience, protests, public demonstrations, insurrection, terrorism, war, cyberterrorism, ransomware or malware, military activity, sabotage, hacking or cybercrime, national or international calamity or any other similar event, including an outbreak or escalation of hostilities involving any Governmental Body or the declaration by any Governmental Body of a national emergency or war, or any worsening of any such conditions; # earthquakes, hurricanes, tsunamis, tornadoes, floods, mudslides, wildfires or other natural disasters, weather conditions, or other force majeure events in the United States or any other country or region in the world (or escalation or worsening of any such events or occurrences, including, in each case, the response of Governmental Body); # pandemics (including the COVID-19 pandemic), epidemics, contagious disease outbreaks or other comparable events (or escalation or worsening of any such events or occurrences), including, in each case, the response of Governmental Bodies (including COVID-19 Measures); # the failure of the Business to meet internal expectations or projections, forecasts, guidance, estimates or budgets (provided, however, that this [clause (g)] shall not be construed as implying that the Seller is making any representation or warranty hereunder with respect to any internal expectations or projections, forecasts, guidance, estimates or budgets, and provided, further, that the underlying facts and circumstances resulting in such failure may be taken into account to the extent not otherwise excluded from this definition pursuant to [clauses [(a) through (f) and (h) through (l)])]])]); # any action taken by the Seller or at the direction of the Purchaser or any action required to be taken by the Purchaser or the Seller pursuant to the terms of this Agreement, or the failure of the Seller to take any action that the Seller is prohibited by the terms of this Agreement from taking or which the Seller did not take on account of the Purchaser withholding its consent thereto; # any breach by the Purchaser of this Agreement; # the availability or cost of equity, debt or other financing to the Purchaser any of its Affiliates; or # any change in any applicable Law (including any applicable COVID-19 Measures) or GAAP or any other applicable accounting principles or standards (or interpretations of any applicable Law (including any applicable COVID-19 Measures) or GAAP or any other applicable accounting principles or standards); provided, however, that any state of facts, circumstance, condition, event, change, development, occurrence or effect arising out of or resulting from any change or event referred to in [clauses [(b) through (f)]] may constitute a Material Adverse Effect to the extent that such change or event has a materially disproportionate impact on the Business compared to other businesses that operate in the industries in which the Business operates.

, (PR NEWSWIRE) -- Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that it has entered into an exclusive licensing agreement with , Ltd, a subsidiary of CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093) for development and commercialization of CRB-701 (SYS6002): a novel clinical stage antibody drug conjugate (ADC) targeting Nectin-4. The agreement covers exclusive commercialization rights to CRB-701 in the United States, Canada, the European Union (including the European Free Trade Area), the United Kingdom, and Australia. CSPC will retain all rights to in the remaining global markets. The IND for CRB-701 has been cleared by the US FDA. CRB-701 is currently being investigated by CSPC in a Phase 1 dose escalation clinical trial in advanced solid tumors in . Corbus is planning to bridge data from this Phase 1 trial to support a US clinical trial starting in . Corbus and CSPC will work collaboratively to execute the clinical development of CRB-701 with Corbus responsible for the clinical development in the US and other licensed territories.

Aggregate Occupancy Rate. The quotient of (a) Net Rentable Area for all of the Unencumbered Properties subject to Leases as to which (i) tenants are in occupancy of their respective leased premises (or as to which a tenant has executed and delivered a lease for space within an Unencumbered Property, which lease is in full force and effect and with respect to which the tenant will take occupancy within ninety (90) days of execution of such lease), (ii) tenants are not in default of any of their monetary or other material obligations under their respective Lease beyond sixty (60) days (excluding year-end reconciliations of CAM charges or similar items and any failure to pay the first month such amount becomes due and payable the incremental increase in annual base rent as a result of the impact of an annual escalation of such rent), (iii) are an arm’s length Lease entered into in the ordinary course of business with a party that is not an Affiliate of the Borrower, and (iv) tenants or any guarantor thereunder are not subject to any bankruptcy, reorganization, arrangement, insolvency, readjustment of debt, dissolution, liquidation or similar debtor relief proceeding, divided by (b) Net Rentable Area for all of the Unencumbered Properties, expressed as a percentage.

On or after the date hereof there shall not have occurred any of the following: # a suspension or material limitation in trading in securities generally on the NYSE or on NASDAQ; # a suspension or material limitation in trading in the Company’s securities on NYSE; # a general moratorium on commercial banking activities declared by either federal or New York authorities or a material disruption in commercial banking or securities settlement or clearance services in the United States; # the outbreak or escalation of hostilities involving the United States or the declaration by the United States of a national emergency or war; or # the occurrence of any other calamity or crisis or any change in financial, political or economic conditions in the United States or elsewhere, including, without limitation, as a result of terrorist activities occurring after the date hereof, if the effect of any such event specified in [clause [(iv) or (v)])]])], in the reasonable judgment of the Representative makes it impracticable or inadvisable to proceed with the public offering or the delivery of the Notes being delivered at the Closing Date or Date of Delivery, as the case may be, on the terms and in the manner contemplated in the Prospectus.

Load more...
Select clause to view document information.

Draft better contracts
faster with AllDrafts

AllDrafts is a cloud-based editor designed specifically for contracts. With automatic formatting, a massive clause library, smart redaction, and insanely easy templates, it’s a welcome change from Word.

And AllDrafts generates clean Word and PDF files from any draft.